{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:31:22Z","timestamp":1786480282327,"version":"build-2736575974"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2022,8,25]]},"DOI":"10.34067\/kid.0000952022","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T15:55:13Z","timestamp":1652889313000},"page":"1442-1444","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Balancing Hyperkalemia Risks with Clinical Benefits of Renin-Angiotensin-Aldosterone Inhibitors\/Mineralocorticoid Receptor Antagonists Blockade: It\u2019s Apples and Oranges"],"prefix":"10.34067","volume":"3","author":[{"given":"Silvia J.","family":"Leon","sequence":"first","affiliation":[{"name":"Chronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5075-6370","authenticated-orcid":false,"given":"Navdeep","family":"Tangri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"B1-20250825","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(11)60178-5","article-title":"Chronic kidney disease","volume":"379","author":"Levey","year":"2012","journal-title":"Lancet"},{"key":"B2-20250825","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.ekir.2021.02.038","article-title":"Hyperkalemia and its association with mortality, cardiovascular events, hospitalizations, and intensive care unit admissions in a population-based retrospective cohort","volume":"6","author":"Hougen","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B3-20250825","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2215\/CJN.07821109","article-title":"Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors","volume":"5","author":"Weir","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B4-20250825","first-page":"1220","article-title":"The use of renin-angiotensin system inhibitors in patients with chronic kidney disease","volume":"35","author":"Leon","year":"2019","journal-title":"Can J Cardiol"},{"key":"B5-20250825","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","author":"Levin"},{"key":"B6-20250825","doi-asserted-by":"crossref","first-page":"e1001971","DOI":"10.1371\/journal.pmed.1001971","article-title":"Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: A systematic review with network meta-analyses [published correction appears in PLoS Med 13: e1002064, 2016 10.1371\/journal.pmed.1002064]","volume":"13","author":"Catal\u00e1-L\u00f3pez","year":"2016","journal-title":"PLoS Med"},{"key":"B7-20250825","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med"},{"key":"B8-20250825","first-page":"CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease [published correction appears in Cochrane Database Syst Rev CD007004, 2020 10.1002\/14651858.CD007004.pub4]","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"B9-20250825","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"B10-20250825","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1001\/archinternmed.2009.284","article-title":"Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy","volume":"169","author":"Weinberg","year":"2009","journal-title":"Arch Intern Med"},{"key":"B11-20250825","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/MNH.0000000000000500","article-title":"New therapies for hyperkalemia","volume":"28","author":"Leon","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B12-20250825","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","article-title":"Potassium homeostasis and management of dyskalemia in kidney diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference","volume":"97","author":"Clase","year":"2020","journal-title":"Kidney Int"},{"key":"B13-20250825","article-title":"Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: A population-based cohort study [published online ahead of print January 25, 2022]","author":"Leon","journal-title":"Am J Kidney Dis"},{"key":"B14-20250825","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","year":"2020","journal-title":"Kidney Int"},{"key":"B15-20250825","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"B16-20250825","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: A meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000952022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:01:39Z","timestamp":1786478499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000952022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000952022","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]},"assertion":[{"value":"2022-05-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}